Annual report pursuant to Section 13 and 15(d)

12. SEGMENT INFORMATION (Details)

v3.8.0.1
12. SEGMENT INFORMATION (Details) - USD ($)
12 Months Ended
Dec. 31, 2017
Dec. 31, 2016
Product sales, net $ 20,679,239 $ 11,060,636
Gross profit 14,488,664 6,997,635
Loss on extinguishment of debt (188,822) 0
Gain on collection of related party notes receivable 0 379,486
Gain on change in derivative liability 248,875 147,200
Impairment of inventory 0 (3,562,459)
Impairment of PhytoSPHERE goodwill and intangible assets 0 (2,746,512)
Royalty buy-out (2,432,000) 0
Selling, general and administrative (16,252,376) (13,129,950)
Research and development (724,329) (1,159,009)
Operating loss (4,859,988) (13,073,609)
Consumer Products [Member]    
Product sales, net 20,679,239 11,060,636
Gross profit 14,488,664 6,997,635
Loss on extinguishment of debt (188,822)  
Gain on collection of related party notes receivable 0 379,486
Gain on change in derivative liability 248,875 147,200
Impairment of inventory   (3,562,459)
Impairment of PhytoSPHERE goodwill and intangible assets   (2,746,512)
Royalty buy-out (2,432,000) 0
Selling, general and administrative (16,016,615) (12,741,211)
Research and development (251,134) (834,963)
Operating loss (4,151,032) (12,360,824)
Specialty Pharmaceuticals [Member]    
Product sales, net 0 0
Gross profit 0 0
Loss on extinguishment of debt 0  
Gain on collection of related party notes receivable 0 0
Gain on change in derivative liability 0 0
Impairment of inventory   0
Impairment of PhytoSPHERE goodwill and intangible assets   0
Royalty buy-out 0 0
Selling, general and administrative (235,761) (388,739)
Research and development (473,195) (324,046)
Operating loss $ (708,956) $ (712,785)